GOLPH3-mTOR Crosstalk and Glycosylation: A Molecular Driver of Cancer Progression

Anna Frappaolo1, Gianluca Zaccagnini1, Maria Grazia Giansanti1

  • 1Istituto di Biologia e Patologia Molecolari del CNR, c/o Dipartimento di Biologia e Biotecnologie, Sapienza Università di Roma, 00185 Roma, Italy.

Cells
|March 26, 2025
PubMed

Insights

Golgi phosphoprotein 3 (GOLPH3) is vital for Golgi structure and cancer progression. Understanding its functions, including roles in trafficking and mTOR signaling, may offer new therapeutic strategies against cancer metastasis.

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Cancer Research

Background:

  • Golgi phosphoprotein 3 (GOLPH3) is a conserved protein crucial for Golgi apparatus function and vesicular transport.
  • Overexpression of GOLPH3 correlates with tumor metastasis and poor prognosis in various cancers.

Purpose of the Study:

  • To review current knowledge on GOLPH3's molecular and cellular functions.
  • To explore potential therapeutic strategies targeting GOLPH3 activity in cancer.

Main Methods:

  • Literature review of proteomic studies, cancer research, and molecular/cellular biology.
  • Analysis of GOLPH3's role in Golgi architecture, vesicular trafficking, and protein interactions.
  • Examination of GOLPH3's association with cancer signaling pathways, including mTOR.

Main Results:

  • GOLPH3 acts as a cargo adaptor for intra-Golgi vesicles and influences glycosylation.
  • GOLPH3-associated defects contribute to malignant phenotypes and enhanced mTOR signaling in cancer.
  • GOLPH3 is essential for cytokinesis and maintaining genomic stability.

Conclusions:

  • GOLPH3 plays a multifaceted role in cellular processes, including Golgi function, cancer progression, and cytokinesis.
  • Targeting GOLPH3 presents a potential therapeutic avenue for inhibiting cancer metastasis and improving patient outcomes.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.3K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.7K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
3.9K